Literature DB >> 20075832

Bendamustine induced neurotoxicity.

Bruce D Cheson1, Michael L Kroll.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20075832

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  6 in total

Review 1.  Bendamustine for treatment of chronic lymphocytic leukemia.

Authors:  Julie Elizabeth Chang; Brad Steven Kahl
Journal:  Expert Opin Pharmacother       Date:  2012-06-05       Impact factor: 3.889

Review 2.  Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 3.  Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

4.  Encephalopathy after Bendamustine Treatment: A Rare Side Effect?

Authors:  Carolina Amado; Gisela Ferreira; Fernando Silva; Mariana Silva Leal; Margarida Cruz
Journal:  Eur J Case Rep Intern Med       Date:  2020-11-03

5.  Bendamustine associated with irreversible ascending paralysis.

Authors:  Ashraf Alhafez; Omar S Aljitawi; Tara L Lin; Siddhartha Ganguly; Sunil Abhyankar; Joseph P McGuirk
Journal:  Case Rep Hematol       Date:  2013-02-27

Review 6.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.